μ-opioid receptor gene variant OPRM1 118 A>G: A summary of its molecular and clinical consequences for pain

Pharmacogenomics

Volumn 14, Issue 15, 2013, Pages 1915-1925

  Walter, Carmen ^a   Doehring, Alexandra ^a   Oertel, Bruno G ^b   Lötsch, Jörn ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

Analgesia; Genetics; Meta analysis; Opioid; Pain; Review

Indexed keywords

ALFENTANIL; BETA ENDORPHIN; DIPRENORPHINE; DYNORPHIN A; ENDOMORPHIN 1; ENDOMORPHIN 2; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; FENTANYL; HYDROMORPHONE; LEUCINE ENKEPHALIN; LEVOMETHADONE; METENKEPHALIN; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; REMIFENTANIL; SUFENTANIL; TRAMADOL;

ALLELE; ANALGESIA; CANCER PAIN; DIZZINESS; DRUG EFFICACY; DRUG POTENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LABOR PAIN; LOW BACK PAIN; MOLECULAR MECHANICS; NAUSEA; NONHUMAN; OPRM1 GENE; PAIN; PHARMACOGENETICS; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VOMITING;

GENETIC VARIATION; HUMANS; PAIN; RECEPTORS, OPIOID, MU;

EID: 84893489593     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.187     Document Type: Review

References (75)

1. Bond C, LaForge KS, Tian M et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95(16), 9608-9613 (1998). (Pubitemid 28506279)
2. Mestek A, Hurley JH, Bye LS et al. The human mu opioid receptor: modulation of functional desensitization by calcium/calmodulin-dependent protein kinase and protein kinase C. J. Neurosci. 15(3 Pt 2), 2396-2406 (1995).
3. Beyer A, Koch T, Schroder H, Schulz S, Höllt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J. Neurochem. 89(3), 553-560 (2004). (Pubitemid 38534141)
4. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J. Neurochem. 103(1), 77-87 (2007). (Pubitemid 47404205)
5. Oertel BG, Kettner M, Scholich K et al. A common human mu-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J. Biol. Chem. 284(10), 6530-6535 (2009).
6. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S. Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J. Neurochem. 112(2), 486-496 (2010).
7. Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V. Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism. J. Neurophysiol. 97(2), 1058-1067 (2007). (Pubitemid 46239487)
8. Lopez Soto EJ, Raingo J. A118G Mu opioid receptor polymorphism increases inhibitory effects on CaV2.2 channels. Neurosci. Lett. 523(2), 190-194 (2012).
9. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280(38), 32618-32624 (2005). (Pubitemid 41368304)
10. Oertel BG, Doehring A, Roskam B et al. Genetic-epigenetic interaction modulates mu-opioid receptor regulation. Hum. Mol. Genet. 21(21), 4751-4760 (2012).
11. Jia D, Jurkowska RZ, Zhang X, Jeltsch A, Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 449(7159), 248-251 (2007). (Pubitemid 47402375)
12. Jurkowska RZ, Anspach N, Urbanke C et al. Formation of nucleoprotein filaments by mammalian DNA methyltransferase Dnmt3a in complex with regulator Dnmt3L. Nucleic Acids Res. 36(21), 6656-6663 (2008).
13. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA. Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc. Natl Acad. Sci. USA 106(26), 10847-10852 (2009).
14. Ramchandani VA, Umhau J, Pavon FJ et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol. Psychiatry 16(8), 809-817 (2011).
15. Mahmoud S, Thorsell A, Sommer WH et al. Pharmacological consequence of the A118G mu opioid receptor polymorphism on morphine-and fentanyl-mediated modulation of Ca(2)(+) channels in humanized mouse sensory neurons. Anesthesiology 115(5), 1054-1062 (2011).
16. Befort K, Filliol D, Decaillot FM, Gaveriaux- Ruff C, Hoehe MR, Kieffer BL. A single-nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276(5), 3130-3137 (2001).
17. Fillingim RB, Kaplan L, Staud R et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J. Pain 6(3), 159-167 (2005). (Pubitemid 40365019)
18. Lötsch J, Stuck B, Hummel T. The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation. Behav. Neurosci. 120(6), 1218-1224 (2006). (Pubitemid 46058695)
19. Zhang W, Chang YZ, Kan QC et al. Association of human micro-opioid receptor gene polymorphism A118G with fentanyl analgesia consumption in Chinese gynaecological patients. Anaesthesia 65(2), 130-135 (2010).
20. Oertel BG, Preibisch C, Wallenhorst T et al. Differential opioid action on sensory and affective cerebral pain processing. Clin. Pharmacol. Ther. 83(4), 577-588 (2008). (Pubitemid 351417060)
21. Lötsch J, Zimmermann M, Darimont J et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine- 6-glucuronide toxicity? Anesthesiology 97(4), 814-819 (2002).
22. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lötsch J. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 16(9), 625-636 (2006). (Pubitemid 44223074)
23. Romberg RR, Olofsen E, Bijl H et al. Polymorphism of mu-Opioid Receptor Gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3), 522-530 (2005). (Pubitemid 40315140)
24. Hirota T, Ieiri I, Takane H et al. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. 31(5), 677-680 (2003). (Pubitemid 36444178)
25. Caraco Y, Maroz Y, Davidson E. Variability in alfentanil analgesia maybe attributed to polymorphism in the mu-opiod receptor gene. Clin. Pharmacol. Ther. 69(2), 63 (2001).
26. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 139(1), 5-14 (2008).
27. Camorcia M, Capogna G, Stirparo S, Berritta C, Blouin JL, Landau R. Effect of mu-opioid receptor A118G polymorphism on the ED50 of epidural sufentanil for labor analgesia. Int. J. Obstet. Anesth. 21(1), 40-44 (2012).
28. Walter C, Lötsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146(3), 270-275 (2009).
29. Klepstad P, Rakvag TT, Kaasa S et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232-1239 (2004). (Pubitemid 39490855)
30. Klepstad P, Fladvad T, Skorpen F et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152(5), 1139-1145 (2011).
31. Mura E, Govoni S, Racchi M et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J. Pain Res. 6, 331-353 (2013).
32. Lötsch J, Doehring A, Mogil JS, Arndt T, Geisslinger G, Ultsch A. Functional genomics of pain in analgesic drug development and therapy. Pharmacol. Ther. 139(1), 60-70 (2013).
33. Lötsch J, Flühr K, Neddermayer T, Doehring A, Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin. Pharmacol. Ther. 85(1), 25-30 (2009).
34. Hastie BA, Riley JL 3rd, Robinson ME et al. Cluster analysis of multiple experimental pain modalities. Pain 116(3), 227-237 (2005). (Pubitemid 40957126)
35. Binder A, May D, Baron R et al. Transient receptor potential channel polymorphisms are associated with the somatosensory function in neuropathic pain patients. PLoS ONE 6(3), e17387 (2011).
36. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 9(8), 807-819 (2010).
37. Lötsch J, Ultsch A. A machine-learned knowledge discovery method for associating complex phenotypes with complex genotypes. Application to pain. J. Biomed. Inform. 46(5), 921-928 (2013).
38. International HapMap C. The International HapMap Project. Nature 426(6968), 789-796 (2003).
39. Doehring A, Küsener N, Fluhr K, Neddermeyer TJ, Schneider G, Lötsch J. Effect sizes in experimental pain produced by gender, genetic variants and sensitization procedures. PLoS ONE 6(3), e17724 (2011).
40. Sia AT, Lim Y, Lim EC et al. Influence of mu-opioid receptor variant on morphine use and self-rated pain following abdominal hysterectomy. J. Pain (2013) (In Press).
41. Fukuda K, Hayashida M, Ide S et al. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 147(1-3), 194-201 (2009).
42. Huedo-Medina TB, Sanchez-Meca J, Marin- Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods 11(2), 193-206 (2006). (Pubitemid 44001277)
43. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557-560 (2003). (Pubitemid 37088507)
44. Cohen J. A power primer. Psych. Bull. 112, 155-159 (1992).
45. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lötsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73(1), 107-121 (2003). (Pubitemid 36158492)
46. Lötsch J, Skarke C, Grösch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12(1), 3-9 (2002). (Pubitemid 34112237)
47. Zwisler ST, Enggaard TP, Noehr-Jensen L et al. The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam. Clin. Pharmacol. 24(4), 517-524 (2010).
48. Lötsch J, Skarke C, Wieting J et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin. Pharmacol. Ther. 79(1), 72-89 (2006). (Pubitemid 43069580)
49. Wand GS, McCaul M, Yang X et al. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26(1), 106-114 (2002). (Pubitemid 34075281)
50. Sia AT, Lim Y, Lim EC et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109(3), 520-526 (2008).
51. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105(2), 334-337 (2006). (Pubitemid 44148178)
52. Chou WY, Yang LC, Lu HF et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol. Scand. 50(7), 787-792 (2006).
53. Reyes-Gibby CC, Shete S, Rakvag T et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1-2), 25-30 (2007). (Pubitemid 46850782)
54. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559-566 (2008). (Pubitemid 351417058)
55. Chen LK, Chen SS, Huang CH et al. Polymorphism of mu-Opioid Receptor Gene (OPRM1:c.118A>G) might not protect against or enhance morphine-induced nausea or vomiting. Pain Res. Treat. 2013, 259306 (2013).
56. Tsai FF, Fan SZ, Yang YM, Chien KL, Su YN, Chen LK. Human opioid mu-receptor A118G polymorphism may protect against central pruritus by epidural morphine for post-cesarean analgesia. Acta Anaesthesiol. Scand. 54(10), 1265-1269 (2010).
57. De Gregori M, Garbin G, De Gregori S et al. Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain. Eur. J. Clin. Pharmacol. 69(9), 1651-1658 (2013).
58. Huehne K, Leis S, Muenster T et al. High post surgical opioid requirements in Crohn's disease are not due to a general change in pain sensitivity. Eur. J. Pain 13(10), 1036-1042 (2009).
59. Boswell MV, Stauble ME, Loyd GE et al. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician 16(3), E227-E235 (2013).
60. Zwisler ST, Enggaard TP, Mikkelsen S et al. Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain. J. Clin. Pharmacol. 52(2), 234-242 (2012).
61. Wu WD, Wang Y, Fang YM, Zhou HY. Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. Mol. Diagn. Ther. 13(5), 331-337 (2009).
62. Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol. 77(1), 33-39 (2011).
63. Landau R, Liu SK, Blouin JL, Carvalho B. The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia. Anesth. Analg. 116(2), 386-391 (2013).
64. Zhang F, Liao Q, Li L et al. The correlation between post-operative fentanyl requirements and -opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy. Exp. Ther. Med. 5(4), 1147-1152 (2013).
65. Rhodin A, Gronbladh A, Ginya H et al. Combined analysis of circulating beta-endorphin with gene polymorphisms in OPRM1, CACNAD2 and ABCB1 reveals correlation with pain, opioid sensitivity and opioid-related side effects. Mol. Brain 6, 8 (2013).
66. Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin-induced painful neuropathy. Cancer 118(6), 1718-1725 (2012).
67. De Capraris A, Cinnella G, Marolla A et al. Micro opioid receptor A118G polymorphism and post-operative pain: opioids' effects on heterozygous patients. Int. J. Immunopathol. Pharmacol. 24(4), 993-1004 (2011).
68. Lötsch J, von Hentig N, Freynhagen R et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet. Genomics 19(6), 429-436 (2009).
69. Henker RA, Lewis A, Dai F et al. The associations between OPRM 1 and COMT genotypes and postoperative pain, opioid use, and opioid-induced sedation. Biol. Res. Nurs. 15(3), 309-317 (2013).
70. Hayashida M, Nagashima M, Satoh Y et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 9(11), 1605-1616 (2008).
71. Klepstad P, Rakvag TT, Kaasa S et al. The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232-1239 (2004). (Pubitemid 39490855)
72. Lötsch J. Basic genetic statistics are necessary in studies of functional associations in anesthesiology. Anesthesiology 107(1), 168-169; author reply 169 (2007). (Pubitemid 46987835)
73. NCBI. dbSNP. www.ncbi.nlm.nih.gov/projects/SNP/snp-ss. cgi?ss=ss28447285
74. The Allele Frequency Database. http://alfred.med.yale.edu/alfred/ SiteTable1A-working.asp?siteuid=SI273135V
75. PubMed. www.ncbi.nlm.nih.gov/sites/entrez